Fesoterodine (BioDeep_00000033367)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate

化学式: C26H37NO3 (411.27732920000005)
中文名称: 弗斯特罗定
谱图信息: 最多检出来源 Homo sapiens(blood) 8.22%

分子结构信息

SMILES: CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2
InChI: InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1

描述信息

Fesoterodine is only found in individuals that have used or taken this drug. It is an antimuscarinic prodrug used for treating overactive bladder syndrome.Fesoterodine, once converted to its active metabolite, 5-hydroxymethyltolterodine, acts as a competitive antagonists at muscarinic receptors. This results in the inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
D000089162 - Genitourinary Agents > D064804 - Urological Agents

同义名列表

4 个代谢物同义名

2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate; Fesoterodine Fumarate; Fesoterodine; Toviaz



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Shinichi Nakanishi. [The Efficacy of Fesoterodine Switched from Solifenacin for Overactive Bladder Patients]. Hinyokika kiyo. Acta urologica Japonica. 2020 Jun; 66(6):165-170. doi: 10.14989/actauroljap_66_6_165. [PMID: 32605354]
  • Yoshihisa Matsukawa, Shun Takai, Tsuyoshi Majima, Yasuhito Funahashi, Naoto Sassa, Masashi Kato, Tokunori Yamamoto, Momokazu Gotoh. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies. Neurourology and urodynamics. 2019 03; 38(3):941-949. doi: 10.1002/nau.23935. [PMID: 30779375]
  • Hong-Goo Lee, Yun-Sang Park, Jin-Hyuk Jeong, Yong-Bin Kwon, Dae Hwan Shin, Ju-Young Kim, Yun-Seok Rhee, Eun-Seok Park, Dong-Wook Kim, Chun-Woong Park. Physicochemical properties and drug-release mechanisms of dual-release bilayer tablet containing mirabegron and fesoterodine fumarate. Drug design, development and therapy. 2019; 13(?):2459-2474. doi: 10.2147/dddt.s212520. [PMID: 31413543]
  • Yu A Kupriyanov, G R Kasyan, D Yu Pushkar. [A role of fesoterodine in treatment of overactive bladder]. Urologiia (Moscow, Russia : 1999). 2018 Dec; ?(6):155-162. doi: 10.18565/urology.2018.6.155-162. [PMID: 30742396]
  • Nikunjkumar Patel, Barbara Wisniowska, Sebastian Polak. Virtual Thorough QT (TQT) Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine. The AAPS journal. 2018 07; 20(5):83. doi: 10.1208/s12248-018-0244-3. [PMID: 29995258]
  • Masayo Oishi, Yuma Takano, Yutaka Torita, Bimal Malhotra, Koji Chiba. Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole. Drug metabolism and pharmacokinetics. 2018 Feb; 33(1):90-95. doi: 10.1016/j.dmpk.2017.11.005. [PMID: 29338933]
  • Johnathan A Khusid, Jeffrey P Weiss, Martin O Carlsson, Erin K Mangan. Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders. The Journal of urology. 2017 11; 198(5):1119-1123. doi: 10.1016/j.juro.2017.04.098. [PMID: 28479240]
  • Soo Rim Kim, Yeo Jung Moon, Sei Kwang Kim, Sang Wook Bai. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome. Yonsei medical journal. 2015 Jan; 56(1):204-11. doi: 10.3349/ymj.2015.56.1.204. [PMID: 25510766]
  • Masayo Oishi, Yoshiro Tomono, Hidetomi Yamagami, Bimal Malhotra. Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations. Journal of clinical pharmacology. 2014 Aug; 54(8):928-36. doi: 10.1002/jcph.274. [PMID: 24619889]
  • Stephen Mock, Roger R Dmochowski. Evaluation of fesoterodine fumarate for the treatment of an overactive bladder. Expert opinion on drug metabolism & toxicology. 2013 Dec; 9(12):1659-66. doi: 10.1517/17425255.2013.858118. [PMID: 24205892]
  • K-S Lee, B Park, J H Kim, H G Kim, J T Seo, J G Lee, Y Jang, M-S Choo. A randomised, double-blind, parallel design, multi-institutional, non-inferiority phase IV trial of imidafenacin versus fesoterodine for overactive bladder. International journal of clinical practice. 2013 Dec; 67(12):1317-26. doi: 10.1111/ijcp.12272. [PMID: 24246210]
  • Jeffrey P Weiss, Zhanna Jumadilova, Theodore M Johnson, Mary P Fitzgerald, Martin Carlsson, Diane L Martire, Atul Malhotra. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. The Journal of urology. 2013 Apr; 189(4):1396-401. doi: 10.1016/j.juro.2012.11.067. [PMID: 23159276]
  • Jignesh M Parekh, Mallika Sanyal, Manish Yadav, Pranav S Shrivastav. Investigation of ex vivo stability of fesoterodine in human plasma and its simultaneous determination together with its active metabolite 5-HMT by LC-ESI-MS/MS: Application to a bioequivalence study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2013 Jan; 913-914(?):1-11. doi: 10.1016/j.jchromb.2012.11.010. [PMID: 23266359]
  • Charalampos Konstantinidis, Michael Samarinas, Sotirios Andreadakis, Stylianos Xanthis, Konstantinos Skriapas. Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin--a prospective study. Urologia internationalis. 2013; 90(2):156-60. doi: 10.1159/000345050. [PMID: 23221480]
  • Dongseong Shin, Kwang-Hee Shin, SeungHwan Lee, Kyoung Soo Lim, Joo-Youn Cho, In-Jin Jang, Sang-Goo Shin, Kyung-Sang Yu. Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers. International journal of clinical pharmacology and therapeutics. 2012 Oct; 50(10):722-8. doi: 10.5414/cp201708. [PMID: 22853865]
  • Bimal Malhotra, Ahmed El-Tahtawy, Ellen Q Wang, Amanda Darekar, Nandini Cossons, Tim J Crook, David Scholfield, Pramod Reddy. Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder. Journal of pediatric urology. 2012 Aug; 8(4):336-42. doi: 10.1016/j.jpurol.2012.02.008. [PMID: 22417681]
  • Bimal Malhotra, Christine Alvey, Jason Gong, Xiaoxi Li, Gregory Duczynski, Kuan Gandelman. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. British journal of clinical pharmacology. 2011 Aug; 72(2):257-62. doi: 10.1111/j.1365-2125.2011.03989.x. [PMID: 21496065]
  • Bimal Malhotra, Maurice Dickins, Christine Alvey, Zhanna Jumadilova, Xiaoxi Li, Gregory Duczynski, Kuan Gandelman. Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. British journal of clinical pharmacology. 2011 Aug; 72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x. [PMID: 21545485]
  • Ernesto Callegari, Bimal Malhotra, Peter J Bungay, Rob Webster, Katherine S Fenner, Sarah Kempshall, Jennifer L LaPerle, Martin C Michel, Gary G Kay. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. British journal of clinical pharmacology. 2011 Aug; 72(2):235-46. doi: 10.1111/j.1365-2125.2011.03961.x. [PMID: 21392072]
  • Stine Mjåvatn Jakobsen, Hege Kersten, Espen Molden. Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay. Journal of the American Geriatrics Society. 2011 Mar; 59(3):501-5. doi: 10.1111/j.1532-5415.2010.03307.x. [PMID: 21391941]
  • Christian de Mey, Lyudmila Mateva, Zahariy Krastev, Richard Sachse, Nolan Wood, Bimal Malhotra. Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine. Journal of clinical pharmacology. 2011 Mar; 51(3):397-405. doi: 10.1177/0091270010365547. [PMID: 20371737]
  • Howard B Goldman, Jon D Morrow, Jason Gong, Li-Jung Tseng, Tim Schneider. Early onset of fesoterodine efficacy in subjects with overactive bladder. BJU international. 2011 Feb; 107(4):598-602. doi: 10.1111/j.1464-410x.2010.09586.x. [PMID: 20868387]
  • Linda Cardozo, Vik Khullar, Ahmed El-Tahtawy, Zhonghong Guan, Bimal Malhotra, David Staskin. Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder. BMC urology. 2010 Aug; 10(?):14. doi: 10.1186/1471-2490-10-14. [PMID: 20723260]
  • Bimal K Malhotra, Penelope H Crownover, Robert LaBadie, Paul Glue, Scott A MacDiarmid. The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. European journal of clinical pharmacology. 2010 Feb; 66(2):171-6. doi: 10.1007/s00228-009-0748-y. [PMID: 19915829]
  • B K Malhotra, N Wood, R Sachse. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. International journal of clinical pharmacology and therapeutics. 2009 Sep; 47(9):570-8. doi: 10.5414/cpp47570. [PMID: 19761716]
  • Bimal Malhotra, Richard Sachse, Nolan Wood. Evaluation of drug-drug interactions with fesoterodine. European journal of clinical pharmacology. 2009 Jun; 65(6):551-60. doi: 10.1007/s00228-009-0648-1. [PMID: 19347334]
  • B Malhotra, R Sachse, N Wood. Influence of food on the pharmacokinetic profile of fesoterodine. International journal of clinical pharmacology and therapeutics. 2009 Jun; 47(6):384-90. doi: 10.5414/cpp47384. [PMID: 19473600]
  • Bimal Malhotra, Kuan Gandelman, Richard Sachse, Nolan Wood. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. Journal of clinical pharmacology. 2009 Apr; 49(4):477-82. doi: 10.1177/0091270009332434. [PMID: 19246724]
  • Hans-Uwe Simon, Bimal Malhotra. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Swiss medical weekly. 2009 Mar; 139(9-10):146-51. doi: smw-12542. [PMID: 19145494]
  • Lambertus P W Witte, Wilhemina M C Mulder, Jean J M C H de la Rosette, Martin C Michel. Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?. Current opinion in urology. 2009 Jan; 19(1):13-9. doi: 10.1097/mou.0b013e32831a6ff3. [PMID: 19057211]
  • B Malhotra, Z Guan, N Wood, K Gandelman. Pharmacokinetic profile of fesoterodine. International journal of clinical pharmacology and therapeutics. 2008 Nov; 46(11):556-63. doi: 10.5414/cpp46556. [PMID: 19000553]
  • Christopher R Chapple, Philip E Van Kerrebroeck, Klaus-Peter Jünemann, Joseph T Wang, Marina Brodsky. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU international. 2008 Nov; 102(9):1128-32. doi: 10.1111/j.1464-410x.2008.07907.x. [PMID: 18647298]
  • Vik Khullar, Eric S Rovner, Roger Dmochowski, Victor Nitti, Joseph Wang, Zhonghong Guan. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008 May; 71(5):839-43. doi: 10.1016/j.urology.2007.12.017. [PMID: 18342923]
  • Victor W Nitti, Roger Dmochowski, Peter K Sand, Hans-Theo Forst, Cornelia Haag-Molkenteller, Ute Massow, Joseph Wang, Marina Brodsky, Tamara Bavendam. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. The Journal of urology. 2007 Dec; 178(6):2488-94. doi: 10.1016/j.juro.2007.08.033. [PMID: 17937959]